Augmentation of the immune response of the murine liver by levamisole.
Murine hepatic nonparenchymal cells (NPC) were studied following in vivo treatment with levamisole. This agent was found to increase the cytolytic action of these cells against YAC-1 and P815 target cells. An increase in the cytostatic activity against liver-derived murine colon adenocarcinoma 38 tumor cells was also observed. Treatment with levamisole also augmented the proliferation of the hepatic NPC. Supernatants generated by these cells contained an agent capable of stimulating the proliferation of bone marrow cells from the same mice. The effect of levamisole on different subsets of NPC derived from the liver in this model is discussed.
Johnkoski
J A
JA
Department of Surgery, State University of New York, Buffalo.
Hsueh
C T
CT
Doerr
R J
RJ
Cohen
S A
SA
D000818:Animals; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology; D003114:Colony-Forming Units Assay; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D007694:Killer Cells, Natural / Q000276:immunology; D007978:Levamisole / Q000494:pharmacology*; D008099:Liver / Q000166:cytology / Q000276:immunology*; D008223:Lymphoma / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D010954:Plasmacytoma / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000276:immunology
D007978:Levamisole